Last reviewed · How we verify
continuation (darbepoetinum)
continuation (darbepoetinum) is a Erythropoiesis-stimulating agent (ESA) Small molecule drug developed by Anemia Working Group Romania. It is currently FDA-approved for Anemia associated with chronic kidney disease, Anemia in patients with non-myeloid malignancies receiving chemotherapy. Also known as: Darbepo Group.
Darbepoetin alfa is an erythropoiesis-stimulating agent that binds to the erythropoietin receptor to stimulate red blood cell production.
Darbepoetin alfa is an erythropoiesis-stimulating agent that binds to the erythropoietin receptor to stimulate red blood cell production. Used for Anemia associated with chronic kidney disease, Anemia in patients with non-myeloid malignancies receiving chemotherapy.
At a glance
| Generic name | continuation (darbepoetinum) |
|---|---|
| Also known as | Darbepo Group |
| Sponsor | Anemia Working Group Romania |
| Drug class | Erythropoiesis-stimulating agent (ESA) |
| Target | Erythropoietin receptor (EPOR) |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
Mechanism of action
Darbepoetin alfa is a recombinant human erythropoietin analog engineered with two additional N-linked carbohydrate chains, which extends its half-life compared to epoetin alfa. It activates the erythropoietin receptor on erythroid progenitor cells in the bone marrow, promoting their proliferation, differentiation, and maturation into mature red blood cells. This mechanism increases hemoglobin levels and reduces the need for blood transfusions in anemic patients.
Approved indications
- Anemia associated with chronic kidney disease
- Anemia in patients with non-myeloid malignancies receiving chemotherapy
Common side effects
- Hypertension
- Thrombovascular events
- Headache
- Injection site pain
- Flu-like symptoms
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- continuation (darbepoetinum) CI brief — competitive landscape report
- continuation (darbepoetinum) updates RSS · CI watch RSS
- Anemia Working Group Romania portfolio CI
Frequently asked questions about continuation (darbepoetinum)
What is continuation (darbepoetinum)?
How does continuation (darbepoetinum) work?
What is continuation (darbepoetinum) used for?
Who makes continuation (darbepoetinum)?
Is continuation (darbepoetinum) also known as anything else?
What drug class is continuation (darbepoetinum) in?
What development phase is continuation (darbepoetinum) in?
What are the side effects of continuation (darbepoetinum)?
What does continuation (darbepoetinum) target?
Related
- Drug class: All Erythropoiesis-stimulating agent (ESA) drugs
- Target: All drugs targeting Erythropoietin receptor (EPOR)
- Manufacturer: Anemia Working Group Romania — full pipeline
- Therapeutic area: All drugs in Hematology
- Indication: Drugs for Anemia associated with chronic kidney disease
- Indication: Drugs for Anemia in patients with non-myeloid malignancies receiving chemotherapy
- Also known as: Darbepo Group
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing